While MedImmune Inc. awaits word from the FDA on the supplemental biologics license application for its flu vaccine and seeks ways to pump sales of Synagis, the firm signed a potential $500 million deal with Infinity Pharmaceuticals Inc. focused on small-molecule cancer drugs targeting heat-shock protein 90 (Hsp90) and the Hedgehog cell-signaling pathway. (BioWorld Today) Read More